Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Dosage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Alternative Dosage Form Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This program summary governs prior authorization and quantity limits for selected alternative dosage form prescription drugs, including oral solutions, suspensions, granules, sprinkle capsules, suppositories, nasal sprays, and sublingual tablets, for listed commercial formulary products and associated generic agents.

    Policy Summary
    PayerPrime Therapeutics
    PolicyAlternative Dosage Form Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeRoutine reviewno material change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for listed alternative dosage-form agents and document the applicable approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Alternative dosage formsProducts subject to the program
    30 daysStandard quantity-limit day supply
    12 monthsStandard prior authorization approval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    26
    Alternative-dosage-form agents or formulations listed
    BoeingClient formulary

    Coverage Criteria

    Initial Alternative Dosage Form Therapy

    Target Agent(s) will be approved when ONE of the following is met:

    ONE of

    • The patient is 12 years of age or younger.<= 12 years
    • ALL of the following

      • The patient has an FDA-labeled indication for the requested agent.
      • The patient does not have any FDA-labeled contraindications to the requested agent.
      • ONE of

        • The oral solid dosage form (prescription or OTC, if applicable) is not clinically appropriate for the patient, including difficulty swallowing tablets or capsules; for sucralfate requests, the patient is unable to dissolve the tablet dosage form in water.

          Chart notes are required.

        • The patient has tried and had an inadequate response to the oral solid dosage form (prescription or OTC, if applicable).

          Chart notes are required.

        • The patient has experienced an adverse reaction or intolerance to the oral solid dosage form (prescription or OTC, if applicable) that is not expected to occur with the requested agent.

          Chart notes are required.

        • The patient has an FDA-labeled contraindication to the oral solid dosage form (prescription or OTC, if applicable) that is not expected to occur with the requested agent.

          Chart notes are required.

    note":"Length of approval: 12 months. If a quantity limit applies, refer to Quantity Limit Criteria."}

    Quantity-Limit Criteria

    Coverage for a requested quantity exceeding the program quantity limit will be approved when ALL of the following are met:

    ALL of the following

    • The requested quantity (dose) exceeds the program quantity limit.
    • ONE of the following dose-justification pathways

      • Pathway A

        • The requested agent does not have a maximum FDA-labeled dose for the requested indication.
        • There is support for therapy with a higher dose for the requested indication.
      • Pathway B

    Initial Therapy Criteria

    Initial Alternative Dosage Form Approval

    Target agents will be approved when ONE of the following is met:

    Initial approval pathways

    • Age pathway: The patient is 12 years of age or younger.<=12 years
    • Clinical justification pathway

      • FDA indication: The patient has an FDA-labeled indication for the requested agent.
      • No agent contraindication: The patient does not have any FDA-labeled contraindications to the requested agent.

    Provider Actions and Denial Risks

    Prior Authorization

    Prior Authorization Required for Listed Alternative Dosage Forms

    Submit prior authorization for the applicable alternative dosage form and identify the requested target brand and corresponding generic agent(s). The program includes the following agents and dosage forms.

    • Katerzia — amlodipine benzoate oral suspension 1 mg/mL
    • Sdamlo — amlodipine besylate oral solution, 2.5 mg, 5 mg, and 10 mg
    • Norliqva — amlodipine besylate oral solution 1 mg/mL
    • Lyvispah — baclofen granules packets, 5 mg, 10 mg, and 20 mg
    • Baclofen — baclofen oral solution 5 mg/5 mL
    • Fleqsuvy — baclofen suspension 25 mg/5 mL
    • Enbumyst — bumetanide nasal spray 0.5 mg/0.1 mL
    • Vyscoxa — celecoxib oral suspension 10 mg/mL
    • Javadin — clonidine hydrochloride oral solution 0.02 mg/mL
    • Tonmya — cyclobenzaprine hydrochloride sublingual tablet 2.8 mg
    • Diphenoxylate with atropine liquid 2.5 mg/0.025 mg per 5 mL

    Product Quantity Limits

    Quantity limit
    ProductIndomethacin
    Quantity limit120 suppositories per 30-day supply
    Dose formSuppositories
    Quantity limit
    ProductSucralfate
    Quantity limit1,200 mL per 30-day supply
    Dose formSuspension

    Program Background

    This is an administrative pharmacy benefit program for selected prescription drugs available in alternative dosage forms. Covered formulations include liquids, suspensions, packets, oral granules, sprinkle capsules, suppositories, nasal sprays, and sublingual tablets. The program applies to the listed commercial formulary products and associated generic agents and addresses prior authorization and product-specific quantity limits.

    Policy Summary
    PayerPrime Therapeutics
    PolicyAlternative Dosage Form Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeRoutine reviewno material change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for listed alternative dosage-form agents and document the applicable approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaProvider Actions and Denial RisksProduct Quantity LimitsProgram Background
    The requested quantity (dose) does not exceed the maximum FDA-labeled dose for the requested indication.
  1. There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
  2. Pathway C

    • The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication.
    • There is support for therapy with a higher dose for the requested indication.
  3. note":"Length of approval: 12 months."}
  4. Qualifying dosage-form justification

    • Solid form not clinically appropriate: The oral solid dosage form, prescription or OTC if applicable, is not clinically appropriate for the patient, including difficulty swallowing tablets or capsules; for sucralfate requests, the patient is unable to dissolve the tablet dosage form in water.

      Chart notes are required.

    • Inadequate response to solid form: The patient has tried and had an inadequate response to the oral solid dosage form, prescription or OTC if applicable.

      Chart notes are required.

    • Solid-form adverse effect: The patient has an adverse effect from the oral solid dosage form that is not expected to occur with the requested agent.

      Chart notes are required.

    • Solid-form contraindication: The patient has an FDA-labeled contraindication to the oral solid dosage form, prescription or OTC if applicable, that is not expected to occur with the requested agent.

      Chart notes are required.

  5. Enalapril maleate oral solution 1 mg/mL
  6. Entresto — sacubitril/valsartan sprinkle capsules 6/6 mg and 15/16 mg
  7. Sotylize — sotalol hydrochloride oral solution 5 mg/mL
  8. Sucralfate suspension 1 g/10 mL
  9. Tezruly — terazosin hydrochloride oral solution 1 mg/mL
  10. Ontralfy — tizanidine hydrochloride oral solution 2 mg/5 mL
  11. Documentation Required

    Alternative Dosage Form Approval Criteria

    The requested alternative dosage form may be approved when the patient is 12 years of age or younger, or when the clinical-appropriateness requirements are met.

    • The requested agent must have an FDA-labeled indication for the patient’s condition.
    • The patient must not have an FDA-labeled contraindication to the requested agent.
    • The request must qualify under one of the documented oral-solid-dosage-form exceptions described in the policy.
    Documentation Required

    Chart Notes Required for Alternative Dosage Form

    Include chart notes supporting why the oral solid dosage form is inappropriate or why the requested alternative is medically necessary. Documentation is required for each applicable exception.

    • Difficulty swallowing prescription or applicable OTC tablets or capsules.
    • For sucralfate, inability to dissolve the tablet dosage form in water.
    • Inadequate response after the patient tried the prescription or applicable OTC oral solid dosage form.
    • An adverse reaction to the oral solid dosage form that is not expected with the requested agent.
    • An FDA-labeled contraindication to the oral solid dosage form that is not expected with the requested agent.
    Documentation Required

    Quantity-Limit Exception Documentation

    For a quantity-limit exception, submit clinical support for the requested higher dose or non-standard quantity. The documentation must address the applicable FDA-labeled maximum dose and why the request cannot be met within the program limit.

    • If no maximum FDA-labeled dose exists for the indication, support therapy with a higher dose.
    • If the requested dose does not exceed the maximum FDA-labeled dose, explain why it cannot be achieved with a lower quantity of a higher strength that remains within the program quantity limit.
    • If the requested dose exceeds the maximum FDA-labeled dose, provide support for therapy with the higher dose.
    Billing Rule

    Quantity Limits Apply

    Claims may be denied or restricted when the product-specific quantity limit is exceeded without an approved exception. Program limits generally apply to a 30-day supply.

    • Indomethacin suppository 50 mg: 120 suppositories per 30 days.
    • Sucralfate suspension 1 g/10 mL: 1,200 mL per 30 days.
    • Baclofen oral solution 5 mg/5 mL: 2,400 mL per 30 days.
    • Diphenoxylate/atropine liquid 2.5 mg/0.025 mg per 5 mL: 1,200 mL per 30 days.
    • Enbumyst 0.5 mg/0.1 mL: 120 devices per 30 days.
    • Entresto sprinkle capsules 6/6 mg and 15/16 mg: 240 capsules per 30 days.
    • Epaned 1 mg/mL: 1,200 mL per 30 days.
    • Fleqsuvy 25 mg/5 mL: 600 mL per 30 days.
    • Indocin suspension 25 mg/5 mL: 1,200 mL per 30 days.
    • Inzirqo 10 mg/mL: 160 mL per 30 days.
    • Javadin 0.02 mg/mL: 3,600 mL per 30 days.
    • Katerzia 1 mg/mL: 300 mL per 30 days.
    • Lopressor 10 mg/mL: 1,200 mL per 30 days.
    • Lyvispah 5 mg, 10 mg, and 20 mg packets: 120 packets per 30 days.
    • Meloxicam/Zybic 7.5 mg/5 mL: 300 mL per 30 days.
    • Naprosyn 125 mg/5 mL: 1,800 mL per 30 days.
    • Norliqva 1 mg/mL: 300 mL per 30 days.
    • Ontralfy 2 mg/5 mL: 2,700 mL per 30 days.
    • Qbrelis 1 mg/mL: 2,400 mL per 30 days.
    • Sdamlo 2.5 mg, 5 mg, and 10 mg: 30 bottles per 30 days.
    • Sotylize 5 mg/mL: 1,920 mL per 30 days.
    • Sprix 15.75 mg/spray: quantity limit applies to bottles for a 30-day supply; the source summary does not specify an amount.
    • Tezruly 1 mg/mL: 600 mL per 30 days.
    • Tonmya 2.8 mg: 60 tablets per 30 days.
    • Vyscoxa 10 mg/mL: 1,200 mL per 30 days.
    Denial Risk

    Failure to Meet Alternative Dosage-Form Criteria

    Requests for an alternative dosage form are at risk for denial when the patient does not meet the qualifying age or clinical criteria, or when required documentation is absent.

    • The patient is older than 12 and the request lacks an FDA-labeled indication, involves an FDA-labeled contraindication to the requested agent, or does not establish a qualifying oral-solid-dosage-form exception.
    • Chart notes do not document difficulty swallowing, inability to dissolve sucralfate tablets, inadequate response, an unexpected adverse reaction, or an applicable contraindication.
    • The requested alternative dosage form is not supported as clinically appropriate under the policy.
    Denial Risk

    Unsupported Quantity-Limit Exception

    A quantity-limit exception may be denied when the requested quantity or dose is unsupported, excessive, cannot be justified under the FDA-labeled dosing criteria, or is not achievable within the program rules.

    • No clinical support is provided for therapy above the program quantity limit or above the maximum FDA-labeled dose.
    • The requested quantity does not exceed the maximum FDA-labeled dose, but the submission does not explain why a lower quantity of a higher strength within the program limit cannot be used.
    • The requested quantity exceeds the maximum FDA-labeled dose without support for therapy with the higher dose.
    • The request is for an excessive or non-standard quantity, or a quantity that is not FDA-labeled for the indication.
    Quantity limit
    ProductBaclofen oral solution 5 mg/5 mL
    Quantity limit2,400 mL per 30-day supply
    Dose formOral solution
    Quantity limit
    ProductDiphenoxylate/atropine liquid 2.5-0.025 mg/5 mL
    Quantity limit1,200 mL per 30-day supply
    Dose formLiquid
    Quantity limit
    ProductEnbumyst 0.5 mg/0.1 mL
    Quantity limit120 devices per 30-day supply
    Dose formNasal spray devices
    Quantity limit
    ProductEntresto sacubitril-valsartan sprinkle capsules 6-6 mg
    Quantity limit240 capsules per 30-day supply
    Dose formSprinkle capsules
    Quantity limit
    ProductEntresto sacubitril-valsartan sprinkle capsules 15-16 mg
    Quantity limit240 capsules per 30-day supply
    Dose formSprinkle capsules
    Quantity limit
    ProductEpaned 1 mg/mL
    Quantity limit1,200 mL per 30-day supply
    Dose formOral solution
    Quantity limit
    ProductFleqsuvy 25 mg/5 mL
    Quantity limit600 mL per 30-day supply
    Dose formSuspension
    Quantity limit
    ProductIndocin 25 mg/5 mL
    Quantity limit1,200 mL per 30-day supply
    Dose formSuspension
    Quantity limit
    ProductInzirqo 10 mg/mL
    Quantity limit160 mL per 30-day supply
    Dose formSuspension
    Quantity limit
    ProductJavadin 0.02 mg/mL
    Quantity limit3,600 mL per 30-day supply
    Dose formOral solution
    Quantity limit
    ProductKaterzia 1 mg/mL
    Quantity limit300 mL per 30-day supply
    Dose formOral suspension
    Quantity limit
    ProductLopressor 10 mg/mL
    Quantity limit1,200 mL per 30-day supply
    Dose formOral solution
    Quantity limit
    ProductLyvispah 5 mg
    Quantity limit120 packets per 30-day supply
    Dose formGranules packets
    Quantity limit
    ProductLyvispah 10 mg
    Quantity limit120 packets per 30-day supply
    Dose formGranules packets
    Quantity limit
    ProductLyvispah 20 mg
    Quantity limit120 packets per 30-day supply
    Dose formGranules packets
    Quantity limit
    ProductMeloxicam/Zybic 7.5 mg/5 mL
    Quantity limit300 mL per 30-day supply
    Dose formSuspension
    Quantity limit
    ProductNaprosyn 125 mg/5 mL
    Quantity limit1,800 mL per 30-day supply
    Dose formSuspension
    Quantity limit
    ProductNorliqva 1 mg/mL
    Quantity limit300 mL per 30-day supply
    Dose formOral solution
    Quantity limit
    ProductOntralfy 2 mg/5 mL
    Quantity limit2,700 mL per 30-day supply
    Dose formOral solution
    Quantity limit
    ProductQbrelis 1 mg/mL
    Quantity limit2,400 mL per 30-day supply
    Dose formOral solution
    Quantity limit
    ProductSdamlo 2.5 mg, 5 mg, and 10 mg
    Quantity limit30 bottles per 30-day supply
    Dose formOral solution
    Quantity limit
    ProductSotylize 5 mg/mL
    Quantity limit1,920 mL per 30-day supply
    Dose formOral solution
    Quantity limit
    ProductSprix 15.75 mg/spray
    Quantity limitQuantity-limit amount not stated; bottles per 30-day supply
    Dose formNasal spray
    Quantity limit
    ProductTezruly 1 mg/mL
    Quantity limit600 mL per 30-day supply
    Dose formOral solution
    Quantity limit
    ProductTonmya 2.8 mg
    Quantity limit60 tablets per 30-day supply
    Dose formSublingual tablets
    Quantity limit
    ProductVyscoxa 10 mg/mL
    Quantity limit1,200 mL per 30-day supply
    Dose formOral suspension